{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:18:32Z","timestamp":1790983112111,"version":"4.1.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Trastuzumab deruxtecan (T-DXd; DS-8201) has emerged as a standard later-line therapy for patients with HER2-mutant non-small cell lung cancer (NSCLC), but the optimal treatment strategy after disease progression using T-DXd remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report the clinical course of a female lung adenocarcinoma patient with a HER2 exon 20 mutation who achieved long-term disease control with T-DXd despite multiple lines of chemotherapy, until interstitial pneumonia occurred when combined with a PD-1 inhibitor. After a two-month treatment break, the patient fully recovered from interstitial pneumonia using corticosteroid therapy. After recovery, two additional lines of chemotherapy were administered but produced limited benefit. Thus, T-DXd was reintroduced to control the worsening disease. Notably, T-DXd rechallenge, administered systemically along with local embolization, again provided clinical benefit despite prior radiographic progression on T-DXd and intervening systemic therapies. Overall, the patient achieved prolonged disease control during rechallenge (progression-free survival &amp;gt;14 months) without recurrence of interstitial lung disease (ILD) despite the extensive prior treatment exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case differs from previously reported rechallenge experiences that mainly describe re-exposure after toxicity-related interruption as the rechallenge reported here followed documented disease progression and multiple intervening regimens, suggesting that, in carefully selected patients with HER2-mutant NSCLC who previously responded to T-DXd, rechallenge after progression could be explored as an option when therapeutic alternatives are limited. However, caution is advised and evidence from prospective and real-world cohorts is needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1832498","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:21:50Z","timestamp":1786335710000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Successful trastuzumab deruxtecan rechallenge after disease progression in a pretreated HER2-mutated lung adenocarcinoma patient"],"prefix":"10.3389","volume":"16","author":[{"given":"Wenji","family":"Yan","sequence":"first","affiliation":[{"name":"Senior Department of Medical Oncology, Chinese People's Liberation Army (PLA) General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Medicine, Nankai University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[{"name":"Senior Department of Medical Oncology, Chinese People's Liberation Army (PLA) General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Hu","sequence":"additional","affiliation":[{"name":"Senior Department of Medical Oncology, Chinese People's Liberation Army (PLA) General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Senior Department of Medical Oncology, Chinese People's Liberation Army (PLA) General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1624124","article-title":"HER2 alterations in non-small cell lung cancer (NSCLC): from biology and testing to advances in treatment modalities","volume":"15","author":"Ismail","year":"2025","journal-title":"Front Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174155","article-title":"HER2 in non-small cell lung cancer: a review of emerging therapies","volume":"14","author":"Uy","year":"2022","journal-title":"Cancers"},{"key":"B3","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3390\/pharmaceutics17050608","article-title":"Efficacy and safety of antibody-drug conjugates for lung cancer therapy: a systematic review of randomized and non-randomized clinical trials","volume":"17","author":"Gallina","year":"2025","journal-title":"Pharmaceutics"},{"key":"B4","doi-asserted-by":"publisher","first-page":"8543","DOI":"10.1016\/j.jtho.2023.09.211","article-title":"Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non-small cell lung cancer (mNSCLC): final analysis results of DESTINY-Lung02","volume":"42","author":"Janne","year":"2024","journal-title":"J Clin Oncol"},{"key":"B5","article-title":"Guidelines of chinese society of clinical oncology: non-small cell lung cancer","volume-title":"Guidelines of Chinese Society of Clinical Oncology: non-Small Cell Lung Cancer","author":"CSoC","year":"2024"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-2025-916","article-title":"Real-world outcomes of trastuzumab deruxtecan as second- or further-line treatment in patients with HER2-mutant metastatic non-small cell lung cancer: a retrospective study","volume":"14","author":"Huang","year":"2025","journal-title":"Trans Lung Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2025.05.012","article-title":"Mechanisms of resistance to antibody-drug conjugates in cancers","volume":"63","author":"Murase","year":"2025","journal-title":"Respir Invest"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-25-0647","article-title":"Trastuzumab deruxtecan resistance via loss of HER2 expression and binding","volume":"16","author":"Chen","year":"2026","journal-title":"Cancer Discov"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non\u2013small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial","volume":"41","author":"Goto","year":"2023","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.07.129","article-title":"Final analysis results and patient-reported outcomes from DESTINY-Lung02\u2014a dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic non\u2013small cell lung cancer","volume":"20","author":"J\u00e4nne","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2023.100628","article-title":"Successful rechallenge of trastuzumab deruxtecan after drug-induced interstitial lung disease in a NSCLC with HER2 mutation: a case report","volume":"5","author":"Nam","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.07.015","article-title":"Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease\/pneumonitis","volume":"36","author":"Rugo","year":"2025","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01455","article-title":"Combination of trastuzumab, pertuzumab, and docetaxel in patients with advanced non\u2013small-cell lung cancer harboring HER2 mutations: results from the IFCT-1703 R2D2 trial","volume":"40","author":"Mazieres","year":"2022","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-17-0749","article-title":"A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model","volume":"17","author":"Iwata","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3237","article-title":"Combining immunotherapy and targeted therapies in cancer treatment","volume":"12","author":"Vanneman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.iotech.2024.100747","article-title":"118MO trastuzumab deruxtecan (T-DXd) and pembrolizumab in immuno-oncology (IO)-naive HER2-expressing or HER2-mutant non-small cell lung cancer (NSCLC): interim analysis of a phase Ib study","volume":"24","author":"Italiano","year":"2024","journal-title":"Immuno-Oncol Technol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102378","article-title":"Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis-focus on proactive monitoring, diagnosis, and management","volume":"106","author":"Swain","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100404","article-title":"Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment","volume":"7","author":"Conte","year":"2022","journal-title":"ESMO Open"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial","volume":"25","author":"Smit","year":"2024","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13194","article-title":"Pembrolizumab-induced interstitial lung disease following thoracic surgery in a patient with non-small cell lung cancer","volume":"10","author":"Fujita","year":"2019","journal-title":"Thorac Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1159\/000526141","article-title":"Risk factors for immune checkpoint inhibitor-related pneumonitis in cancer patients: a systemic review and meta-analysis","volume":"101","author":"Zhou","year":"2022","journal-title":"Respiration Int Rev Thorac Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"100554","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"key":"B23","doi-asserted-by":"publisher","first-page":"103651","DOI":"10.1016\/j.jtho.2026.103651","article-title":"Systemic and intracranial efficacy and safety of trastuzumab deruxtecan in patients with HER2-mutant NSCLC across treatment lines: evidence from the TRACER\/HERTras real-world cohort","volume":"21","author":"Illini","year":"2026","journal-title":"J Thorac Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503704","article-title":"Zongertinib in previously treated HER2-mutant non-small-cell lung cancer","volume":"392","author":"Heymach","year":"2025","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.16_suppl.8504","article-title":"SOHO-01: safety and efficacy of BAY 2927088 in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC) who were pretreated but na\u00efve to HER2-targeted therapy or had not received any treatment for advanced disease","volume":"43","author":"Loong","year":"2025","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"100875","DOI":"10.2139\/ssrn.4962238","article-title":"Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: a brief report","volume":"42","author":"Illini","year":"2024","journal-title":"Cancer Treat Res Commun"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1832498\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:21:54Z","timestamp":1786335714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1832498\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":26,"alternative-id":["10.3389\/fonc.2026.1832498"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1832498","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"article-number":"1832498"}}